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Abstract
Background:  The major limit to colorectal cancer screening effectiveness is often low
compliance. We studied the reasons for non compliance and determinants of compliance to faecal
occult blood tests in Lazio, Italy.
Methods: This is a case-control study nested within a trial that tested the effect of type of test and
provider on colorectal cancer screening compliance. Non compliant trial subjects were classified
as cases, and compliant subjects were classified as controls. We sampled 600 cases and 600
controls matched by their general practitioner, half were invited for screening at the hospital, and
the other half directly at their general practitioner's office. Cases and controls answered questions
on: distance from test provider, logistical problems, perception of colorectal cancer risk,
confidence in screening efficacy, fear of results, presence of colorectal cancer in the family, and
gastrointestinal symptoms.
Results: About 31% of cases never received the letter offering free screening, and 17% of the
sampled population had already been screened. The first reported reason for non-compliance was
"lack of time" (30%); the major determinant of compliance was the distance from the test provider:
odds ratio >30 minutes vs <15 minutes 0.3 (95%CI = 0.2–0.7). The odds ratio for lack of time was
0.16 (95% IC 0.1–0.26). The effect was stronger if the hospital (0.03 95%CI = 0.01–0.1) rather than
the general practitioner (0.3 95%CI = 0.2–0.6) was the provider. Twenty-two percent of controls
were accompanied by someone to the test.
Conclusion: To increase compliance, screening programmes must involve test providers who are
geographically close to the target population.
Background
The efficacy of colorectal cancer screening (CRCS) using
faecal occult blood tests (FOBT) in reducing colorectal
cancer (CRC) mortality in the 50–75 year old population
has been demonstrated in large randomised trials[1]. The
reduction in mortality by screening is strictly linked to its
ability to involve as many people among the target popu-
lation as possible. The scientific literature about the rea-
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sons for non compliance has generated few definitive
operational recommendations [2-6]. Some reviews have
summarized the knowledge and indications that have
emerged from the literature[4,5,7]. Some studies have
identified several factors associated with higher preva-
lence of FOBT use: presence of symptoms and a family
history of CRC are associated with higher prevalence,
while the opposite is true for smoking habits. No consist-
ent relation with gender or socio-economic status has
been observed. Other indications come from intervention
studies, and the recommendations are consistent: the
involvement of one's own physician, phone and mail
reminders, and one sample tests all increase compliance.
Some prospective studies have found that a previous
FOBT was a predictor of compliance, while some studies
have found that participation decreased after 75 years of
age. Most studies tested a hypothesis based on the Health
Belief Model[8]. Finally, several surveys have studied the
reasons for non compliance: practical reasons ranked first
in most of the studies; not having health problems was
also a frequent answer, along with anxiety and embarrass-
ment.
The Agency for Public Health of Lazio, Italy, designed a
series of studies in order to implement an evidence-based
CRCS program; a special focus was given to the barriers to
screening, and how to obtain high screening compliance
[9-12].
Study designs Figure 1
Study designs. The figure illustrates the design of the three linked studies. The white box represents the reference popula-
tion; the light grey boxes refer to the survey; the dark grey boxes to the trial; and the shadowed boxes to the case control 
study.
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In this study we analysed self-reported reasons for non
compliance, individual and environmental determinants
of screening compliance, and the interaction between
them.
Population and methods
Setting
Lazio has 5.3 million inhabitants and includes the metro-
politan area of Rome (2.9 million). The CRCS target pop-
ulation (50–74 year olds) is 1.5 million. The health
service is organised into 12 Local Health Units, which
include 50 districts.
The study design (figure 1)
The study design has been described elsewhere[9]; here
we summarize the principal characteristics. We selected an
opportunity sample of 13 hospitals, out of 20 who will
participate in the screening programme in the near future,
in order to represent all types of gastroenterology units (5
university hospitals, 2 large research hospitals, 6 local
hospitals) and all geographic areas (7 in the metropolitan
area of Rome, 2 in the outskirts of Rome, 4 in towns and
small cities of the province). From June 2002 to April
2003, all GPs with an office in the 13 hospital districts
selected (1192) were surveyed[10] and asked to partici-
pate in the randomised trial.
In each of the 13 districts, we sampled 10 GPs of the
24.5% (292/1194) who had agreed to participate. The
sampled GPs were randomised as follows: in each district,
five were assigned to the immunochemical test and five to
the Guaiac test (Guaiac Hemo-Fec, Roche Diagnostic,
Mannheim Germany, and immunochemical OC-Hemo-
dia, Eiken, Tokio Japan, distributed by Alpha Wasserman,
Milan Italy). We sampled 2/10 of the target practice pop-
ulation for each GP; 1/10 of the GP's beneficiaries were
randomised to the GP arm and 1/10 to the hospital arm.
The coordinating centre mailed a letter to the population
sample: for the half randomised to the GP arm, the letter
invited patients to pick up and return the FOBT at the GP's
office; for the half randomised to the hospital arm, the let-
ter invited the patient to pick up and return the FOBT at
the hospital. The study was submitted and approved by
the Committee for Ethics in Screening of the Regional
Agency for Public Health, 16th June 2002, approval n° 1.
Informed consent is not required for this type of study.
Questionnaire response rate Figure 2
Questionnaire response rate. Response to the questionnaire and technical obstacles to screening compliance. The arrows 
show 12 cases reclassified as controls and 6 controls reclassified as cases during the interview.
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We defined the non-compliant population as cases, and
the compliant population as controls. We sampled about
600 cases and 600 controls matched by GP and arm of
randomisation. The matched design was imposed to
exclude practices with too high or too low compliance
because in these extreme situations we had a strong imbal-
ance between cases and controls. We excluded practice
populations with compliance lower than 20% and higher
than 80% in the GP arm and practice populations with a
compliance lower than 10% in the hospital arm (figure
2).
For the 1200 people sampled we looked for updated tele-
phone numbers and delivered brief telephone question-
naires about the reasons for non-compliance to the cases,
and about the reasons for compliance to the controls. We
inquired about distance from the provider, logistical
problems, perception of CRC risk, confidence in screening
efficacy, fear of the results, family history of CRC, and gas-
trointestinal symptoms[13].
Analysis
Demographic factors, gender, age and residence, were
analysed using the entire population participating in the
trial, i.e. 7309. All the other information was available
only for the sample interviewed.
When analysing the trial population, logistic models were
constructed taking into account the effect of the GP clus-
ters; when analysing the case control sample, we adjusted
for GP and provider. We tested the goodness of fit of the
models using the Hosmer and Lemeshow test for deciles
of probability[14]. All analyses were performed using
Stata 7.0 statistical software[15]. Residence was catego-
rised as follows: Rome, cities with a gastroenterology cen-
tre, and cities without a centre. We also categorized the
cities based on the number of inhabitants. We alternated
the two in a logistical model and compared the pseudo r
squared and the goodness of fit.
General Practitioners' exclusion criteria Figure 3
General Practitioners' exclusion criteria. General Practices which obtained extremely low or extremely high compliance 
during the trial (grey areas), were excluded from the survey on reasons for compliance or non compliance.
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Sample size and power of the studies
Trial
The study size was calculated for the main objective of the
trial and is described elsewhere[9]. The study has a power
of 95%, with alpha 0.05, to detect a 20% difference in
compliance between the less represented age class and the
rest of the sample. The power reduction due to provider
interaction, and to the subsequent stratified analysis,
allowed us to detect a difference of 27%.
Case control
The sample size was calculated to obtain a power of 80%,
with alpha .05, to detect a difference in exposure preva-
lence of 1/3 and a lowest prevalence of exposure of 30%.
The expected response rate was 60%. The resulting sample
size was 600 cases and 600 controls.
Results
The never-reached
Figure 2 shows the compliance of cases and controls to the
case-control interview. The percentage of people not
reachable for the interview was higher among the non
compliant than in the compliant group (34.1% vs.
25.0%). The percentage of refusals shows the same group
differences but is lower in both groups (2.7% vs. 1.6%).
Eighty of the interviewed people who were non-compli-
ant to screening (22.5%) declared not having received any
letter inviting them to participate in the programme and
they were excluded from the following analysis (figure 3).
The already-reached
Fifty-four non compliant people declared that they had
already been screened, 20 by FOBT in the previous two
years, 38 by colonoscopy in the previous 10 years and 21
by double contrast barium enema (DCBE) in the previous
10 years (some people had more than one test). They were
excluded from the following analysis. On the other hand,
we found 82 controls who had already been screened: 11
by FOBT, 60 by colonoscopy, and 28 by DCBE. These con-
trols were included in the analysis. None of the inter-
viewed people declared to have had a sigmoidoscopy. The
136 people who had already been screened, when com-
pared with the entire interviewed population, were
slightly more likely to be male (55.2%; 95%CI 46.4–
Table 1: Logistic regression for determinants of non compliance, data from randomised controlled trial. All the Odds Ratios are 
adjusted by age, residence, provider and age if possible.
total males females
FOBT screening OR 95%CI FOBT screening OR 95%CI FOBT screening OR 95%CI
no yes no yes no yes
demographics
Gender*
male 2269 1099 1 -
female 2585 1342 1.12 1.0–1.3
Age*
50–54 1126 464 1.00 - 539 201 1.0 - 581 262 1.0
55–59 916 457 1.34 1.2–1.6 457 202 1.4 1.1–1.9 456 255 1.3 1.0–1.6
60–64 950 449 1.27 1.1–1.5 440 194 1.4 1.1–1.9 510 255 1.1 0.89–1.4
65–69 844 460 1.44 1.2–1.7 386 229 1.8 1.4–2.3 457 231 1.2 0.94–1.5
70–74 738 326 1.22 1.0–1.5 317 140 1.5 1.1–2.0 421 186 1.1 0.82–1.4
logistics and demographics
Residence*
Rome 2832 1285 1.00 - 1284 573 1.0 - 1540 710 1.0
towns with gastroenterology unit 1327 763 1.55 1.1–2.2 652 322 1.6 1.2–2.2 673 441 1.7 1.3–2.2
other towns 566 333 1.13 0.73–1.7 265 174 1.2 0.73–1.9 299 159 1.1 0.70–1.8
logistics
provider
hospital 3028 600 1.0 1388 276 1.0 1631 324 1.0
GP 1838 1843 6.0 5.3–6.8 881 823 5.7 4.7–6.8 954 1018 6.3 5.3–7.4
* For 14 people gender was unknown, for 579 age was unknown, for 203 residence was unknown.BMC Public Health 2005, 5:139 http://www.biomedcentral.com/1471-2458/5/139
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Table 2: Logistic regression for determinants of non compliance, data from questionnaire. All the Odds Ratios are adjusted by age, 
gender and provider.
non compliant compliant OR* 95% CI
demographics
employment status
currently employed 69 91 1
homemaker 76 223 2.2 1.3 3.7
retired 53 81 1.1 0.6 1.9
unemployed 2 5 1.8 0.3 9.6
m.i. 27 10
psychological and cultural
educational level
0–4 years of study 18 17 1
5–7 years of study 53 119 2.5 1.2 5.2
8–12 years of study 35 83 2.5 1.1 5.6
high school graduate 49 117 2.7 1.3 6.0
university 24 46 2.1 0.9 5.1
m.i. 48 28
Gastrointestinal symptoms
no 198 291 1
yes 29 119 2.7 1.7 4.2
CRC cases among relatives
No 212 351 1
yes 15 51 1.8 1.0 3.2
logistics
lack of time 69 25 0.2 0.1 0.3
distance
1–15 min 122 301 1
15–30 44 75 0.8 0.5 1.3
>30 21 15 0.3 0.2 0.7
m.i 40 19
type of transportation
public 31 29 1
private 117 218 2.1 1.2 3.7
on foot 67 159 2.1 1.1 4.1
m.i. 12 4
Analysis stratified by provider:
in the hospital arm
lack of time 32 4 0.04 0.01 0.12
in the GP arm
lack of time 37 21 0.3 0.2 0.6
63.8), to live outside of Rome (46.7%; 95%CI 38.3–
55.8), were significantly older (test for linear trend
chi2(1) = 6.93; Pr>chi2 = 0.0085), had a significantly
higher prevalence of gastrointestinal symptoms (39.0%;
95%CI 30.7–47.7), more CRC cases among relatives
(16,2%; 95%CI 10.4–23.4), and were more likely, with
border-line significance, to agree to a new FOBT screening
(OR 1.5; 95%CI 1.0–2.3; adjusted for GP, provider, age,
gender and residence).
Analysis of demographics
We used the entire population involved in the trial, 7320
individuals, to analyse the effect of most demographic fac-
tors. Women were significantly more compliant, although
the size of this effect is small. Compliance increased in
men with age until 65–69, and than decreased slightly;
among women we did not observe any clear age trend.
There was higher compliance outside Rome in medium-
sized towns with gastroenterology centres, while peopleBMC Public Health 2005, 5:139 http://www.biomedcentral.com/1471-2458/5/139
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living in small towns and rural areas without centres
showed low compliance. Table 1 shows the figures
described above and reports the provider effect, i.e. hospi-
tal and GPs, tested in the trial.
We also considered employment status, information only
available for the case control study sample. Employed and
retired people had the same low level of compliance,
while homemakers had a significantly higher level of
compliance (OR 2.2; 95%CI 1.3–3.7; table 2).
Reasons for non-compliance
Only 24 people of the 350 interviewed (6.9%) picked up
the test but did not return it, consequently we did not per-
form separate analyses for initial agreement and actual
compliance. Very few people answered the proposed jus-
tifications for non-compliance. Table 3 shows the justifi-
cations given by the non-compliant, multiple choice
answers selected are indicated with a star, and others were
summarized from the open answers. The most frequent
answer was "lack of time" (30%), followed by "feel
healthy" (8%) and "ill during the study" (6%). Less than
ten people chose any of the other answers. About 40% did
not respond. Nine people declared to be covered but did
not report how or when they were last tested.
Logistical barriers
We observed compliance that was three times higher at
GP's office than at hospital gastroenterology centres.
There was one gastroenterology centre per district, while
there were 10 GPs' offices per district. In the case control
study we compared the travelling time to the GP office
and to the hospital in the two study arms: 84% stated it
took less than 15 minutes to reach the GP, 12% reported
15–30 minutes, and 4% >30 minutes, while in the hospi-
tal arm, 58% stated less than 15 minutes, 29% 15–30
minutes, and 13% >30 minutes (test for linear trend
chi2(df1) = 55.3; P < 0.00005). Also in the multivariate
analysis, the time required to reach the test provider was a
strong determinant of compliance: odds ratio of 15–30
minutes versus <15 minutes 0.8 (95%CI 0.5–1.3) >30
minutes versus <15 minutes 0.3 (95%CI 0.2–0.7). We
compared also the odds of people declaring "lack of time"
to perform the test in the compliant and non compliant
populations: the odds ratio was 0.16 (95%CI 0.1–0.26)
indicating that it is strongly associated with non compli-
ance. The provider was an effect modifier of the "lack of
time" barrier: the odds ratio is 0.03 (95%CI 0.01–0.1) in
the hospital arm and 0.3 in the GP arm (95%CI 0.2–0.6)
(table 2).
Cultural, psychological and emotional barriers
The effect of the educational level was observed for people
with fewer than 5 years of education. Anxiety regarding
results was reported by 17.8% of the compliant popula-
tion, fear of the test by 8.8%, and embarrassment by
3.9%. Having gastrointestinal symptoms at the moment
of contact is a determinant of compliance: odds ratio 2.7
(95%CI 1.7–4.2). An effect with borderline statistical sig-
nificance was also observed for people with a family his-
tory of CRC: odds ratio 1.8 (95%CI 1.0–3.2).
Chaperones
Ninety (22%) of the 410 compliant people interviewed
were accompanied by someone to the hospital or GP
office: 86 by a relative, 2 by a friend, and 2 by an attend-
ant. There was a slightly higher proportion of people >70
years old (31%), without a clear age trend, and of females
(25%), although neither was statistically significant.
Chaperones were more common outside of Rome (27%,
chi2 = 4.6, p = 0.033) and when the hospital was the pro-
vider (34%, chi2 24.8, p < 0.0005).
Discussion
Limits
The response rate for the case control is acceptable, while
the participation rate among the GPs is very low and gen-
erates several concerns regarding the validity of the overall
observed compliance. The difficulty in involving GPs is a
well-known problem and can reduce study validity[16].
Nevertheless the comparisons between compliant and
non-compliant populations are not affected by the GPs'
self-selection; these comparisons are more likely to be
biased on the differences in response rates between cases
(non-compliant to FOBT) and controls (compliant to
FOBT).
We did not design this study to be a survey of the Lazio
population, although the population sampled for the trial
Table 3: Reason for non compliance
reasons for non compliance to the screening N %
total 227
none declared 89 39.2
*lack of time 70 30.8
*feel healthy 18 7.9
ill 14 6.2
*it was impossible to contact the provider 9 4.0
already covered 9 4.0
do not want 7 3.1
*anxiety over outcome 6 2.6
*the letter was not clear about what I was expected to do 6 2.6
*embarassed by test execution 6 2.6
away from home during study 4 1.8
*fear about risks of the test 3 1.3
oversight 3 1.3
*negatively advised 1 0.4
bleeding (hemorroids) 1 0.4
* Proposed aswersBMC Public Health 2005, 5:139 http://www.biomedcentral.com/1471-2458/5/139
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and for the nested case control was a large sample, which
was not self-selected.
In designing the study we overestimated the power of the
case control. In fact, of 356 non-compliant case inter-
views, only 227 were informative.
Because of the low percentage in the trial of people that
picked up the test but did not return it (8.6%), and conse-
quently also in the case control sample (6.9%), we did not
perform a separate analysis on initial agreement to partic-
ipate in screening and actual compliance. We can only
affirm that the immunochemical test led to a higher per-
centage of returned tests than the guaiac test[11].
The questionnaire may underestimate cultural barriers
like fear of the test or anxiety about the results, both due
to lack of awareness of the people interviewed, and to the
limits of telephone interviews [4].
Never-reached
A high proportion of not reached people means the
screening programme was inequitable, and due to admin-
istrative mistakes denied some their opportunity to be
tested. This group can be estimated as the people who did
not receive the letter, plus the difference between not con-
tacted cases and not contacted controls. We estimated that
22% + (34% – 25%) = 31%; about one-third of the non
compliant population (about 20% of target population)
was not reachable by letter. We had only self-reported
information about receiving the letter, and could not ver-
ify if in fact the letter had been delivered to the right
address and then thrown away. From mammography
screening experience, we know that anywhere from 3% to
18% of letters were returned to sender. This was the most
relevant barrier we observed for the screening programme,
an issue which other researchers have also highlighted
[17-19].
Subjects reached
This case control study, with the limits described above, is
the first survey in our region to explore CRC screening
coverage. The proportion of people screened with one of
the recommended tests is 15.4% among non compliant
and 19.8% among compliant people, and considering
that 35% of the general population is compliant, we esti-
mate 17% coverage with an unknown confidence interval.
This coverage level is lower than what was found in the
USA[20]. The absence of flexosigmoidoscopy in our sam-
ple reflects the scarce use of this technique by Italian
endoscopists, although some may confuse sigmoidoscopy
with colonoscopy. Colonoscopy is the most common test,
accounting for 70% of coverage, and consequentially may
explain the very low level of coverage. The screening of
high risk groups, such as people with symptoms or with
family history of CRC, for whom colonoscopy (or DBCE)
is recommended by the guide-lines[21], represents about
one half of the covered population (47.8%).
Reported motivations for non-compliance
Many people did not provide a motive for non-compli-
ance to screening, and those who did often did not use the
answers provided. This may be one of the limits of the
questionnaire used: Closed questions with a long list of
multiple choices are not well adapted with telephone
interviews. Furthermore the proposed answers were based
on the Health Belief Model[8], which does not adapt well
to the realities screening non-compliance in our setting.
The most common justification was "lack of time" fol-
lowed by feeling healthy, two indicators of a low percep-
tion of susceptibility, rather than of the severity or of the
perception of risks and benefits of the test[22,23].
Logistical barriers
Our results show that the major determinant of non com-
pliance to CRC screening was the "lack of time". We inter-
pret all of the following factors as time-related: 1) the
higher compliance found among women and homemak-
ers in particular, consistent with other Italian studies[13];
2) the higher compliance found in medium-sized towns
with a gastroenterology unit which are the easiest places
to be tested; 3) higher compliance found among subjects
allocated to the GP arm, where the doctor's office is more
easily reachable than the gastroenterology centre, where
"reachable" may be a mix of familiarity, distance, and
expected waiting time; 4) the single evacuation test
(immunochemical) obtained a 20% higher compliance
than the three evacuation test (Guaiac) [11]; 5) more time
was reportedly required to reach the provider in the non
compliant group than in the compliant group; 6) finally,
the lowest odds ratio was observed for "lack of time", and
the most frequent justification was "lack of time".
Subjects who reported to live close to the provider were
more likely to comply. While in the majority of studies
that have addressed this topic[5] the logistical reasons for
non compliance have ranked first, the effect of distance
from the test provider has not yielded consistent
results[24,25]. In our study the self-reported time to reach
the test provider reflects perceived distance that may
reflect the degree of willingness to perform the test; from
this point of view it is not surprising that the effect of per-
ceived distance on compliance was more important in the
hospital arm than in the GP arm. This finding suggests
that interventions should make it easier for patients to
understand how to incorporate this important and non
time-consuming task into their lifestyle.BMC Public Health 2005, 5:139 http://www.biomedcentral.com/1471-2458/5/139
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Cultural, psychological and emotional barriers
In our study we observed the paradox that fear of the test
and anxiety over the results were more frequent in those
who took the test than in those who did not. The problem
could be with the timing of the interview. We contacted
the compliant group after testing, so the questions were
connected to something that had already occurred; the
non compliant population had to base their answers on a
hypothetical situation[4,22].
Other reasons for our difficulties in understanding the
psychological and cultural barriers may have been the
poor fit of the Health Belief Model we used. Other authors
have found similar difficulties using this model[22,26].
Nevertheless there are indications that cultural and psy-
chological barriers exist: 1) the underestimation of the
problem is evident in most of the reasons given by the
non compliant, and confirmed by the strong positive
effect the presence of symptoms and family history of
CRC have on compliance; 2) the anxiety produced by
screening, as well as logistical problems of being screened,
may be inferred from the high percentage of people who
were accompanied to screening; this group surprisingly
consisted not only of old women, but also middle-aged
men.
Conclusion
To increase compliance, screening programmes must
make all efforts possible to involve test providers who are
geographically close to the target population.
Our population suggested one way to overcome logistical
and psychological barriers may be to invite all target indi-
viduals from a single household or block for testing on the
same day[27].
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